Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* breast cancer with measurable locally recurrent or metastatic lesions;~* candidate for chemotherapy;~* HER2-positive disease;~* ECOG PS of \<=2.~Exclusion Criteria:~* previous anticancer therapy for metastatic breast cancer;~* previous radiotherapy for metastatic breast cancer (except for adjuvant radiotherapy \>=6 months before enrollment);~* chronic daily treatment with corticosteroids (\>=10mg/day), aspirin (\>325 mg/day) or clopidogrel (\>75mg/day);~* other primary tumor within last 5 years, except for adequately treated cervical cancer in situ, squamous or basal cell skin cancer;~* uncontrolled hypertension or significant cardiovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).